Compare Enbridge Inc (ENB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Enbridge Inc trades at $51.68 (market cap $112.26B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Enbridge Inc is the larger of the two by market cap, and Enbridge Inc pays the higher dividend (5.36%). Which is the better fit depends on your goals.
| ENB | REGN | |
|---|---|---|
Market Cap | $112.26B | $83.19B |
Sector | Energy | Health |
52-Week High | $58.04 | $812.27 |
52-Week Low | $45.23 | $555.51 |
Enterprise Value | $196.07B | $77.90B |
Dividend Yield | 5.36% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $51.28, down 0.81% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.46, beating estimates, and maintains a strong dividend track record with recent payouts of $0.97. Revenue grew to $65.19B in 2025, with a net income margin of 7.34%, though debt levels have increased.
Outlook is mixed; analyst consensus is evenly split between Buy and Hold, with a 48% Buy rating. Key opportunities include a $41B project backlog and consistent dividend growth, while risks involve high debt, regulatory challenges, and volatile cash flows. The stock's valuation appears reasonable with a P/E of 27.74.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
